Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)
Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1-dependent and -independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atheroscle...
Gespeichert in:
| Veröffentlicht in: | Diabetes care 2016-01, Vol.39 (1), p.139-148 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 148 |
|---|---|
| container_issue | 1 |
| container_start_page | 139 |
| container_title | Diabetes care |
| container_volume | 39 |
| creator | Mita, Tomoya Katakami, Naoto Yoshii, Hidenori Onuma, Tomio Kaneto, Hideaki Osonoi, Takeshi Shiraiwa, Toshihiko Kosugi, Keisuke Umayahara, Yutaka Yamamoto, Tsunehiko Yokoyama, Hiroki Kuribayashi, Nobuichi Jinnouchi, Hideaki Gosho, Masahiko Shimomura, Iichiro Watada, Hirotaka |
| description | Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1-dependent and -independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
This prospective, randomized, open-label, blinded-end point, multicenter, parallel-group, comparative study included 341 patients with T2DM free of a history of apparent cardiovascular diseases recruited at 11 clinical units and randomly allocated to treatment with alogliptin (n = 172) or conventional treatment (n = 169). Primary outcomes were changes in mean common and maximum intima-media thickness (IMT) of the carotid artery measured by carotid arterial echography during a 24-month treatment period.
Alogliptin treatment had a more potent glucose-lowering effect than the conventional treatment (-0.3 ± 0.7% vs. -0.1 ± 0.8%, P = 0.004) without an increase of hypoglycemia. Changes in the mean common and the right and left maximum IMT of the carotid arteries were significantly greater after alogliptin treatment than after conventional treatment (-0.026 mm [SE 0.009] vs. 0.005 mm [SE 0.009], P = 0.022; -0.045 mm [SE 0.018] vs. 0.011 mm [SE 0.017], P = 0.025, and -0.079 mm [SE 0.018] vs. -0.015 mm [SE 0.018], P = 0.013, respectively).
Alogliptin treatment attenuated the progression of carotid IMT in patients with T2DM free of apparent cardiovascular disease compared with the conventional treatment. |
| doi_str_mv | 10.2337/dc15-0781 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1751669368</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1751669368</sourcerecordid><originalsourceid>FETCH-LOGICAL-a371t-48b88db2b552e56bf8c207dbcef13e91d4f74a4a21d175786a8ac5d48903ef043</originalsourceid><addsrcrecordid>eNplkdFu0zAUhi0EYmVwwQsgS9xs0gJ2bCcOd1HXjUmTqLQiLiMnPl49pXFmO5P6qLwNzlpAghv72P7-8x_rR-g9JZ9yxsrPuqMiI6WkL9CCVkxkQnD5Ei0I5VUmqio_QW9CeCCEcC7la3SSF0UuOa0W6Gfdu_vejtEOF1jhSztCqvW-x-vnQgXAHN8MW9va6PwFXnt4giEGHLeQDu7eQwjWDdgZvFTeJQ2u05t3oevn1QZsB7xW0T7Lfti4xZv9CDhPbqqFCOEL3qRmd3HS-7nN0cI-AV4ZA11Spdu_g-LkdpDa7j-vs7v1qr7M6vO36JVRfYB3x_0Ufb9abZZfs9tv1zfL-jZTrKQx47KVUrd5K0QOomiN7HJS6rYDQxlUVHNTcsVVTjUtRSkLJVUnNJcVYWAIZ6fo7NB39O5xghCbnQ0d9L0awE2hSSpaFBUrZEI__oM-uMkPabqZKgkrGJup8wPVpR8FD6YZvd0pv28oaea8mznvZs47sR-OHad2B_oP-Ttg9guiFaeY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1757036338</pqid></control><display><type>article</type><title>Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Mita, Tomoya ; Katakami, Naoto ; Yoshii, Hidenori ; Onuma, Tomio ; Kaneto, Hideaki ; Osonoi, Takeshi ; Shiraiwa, Toshihiko ; Kosugi, Keisuke ; Umayahara, Yutaka ; Yamamoto, Tsunehiko ; Yokoyama, Hiroki ; Kuribayashi, Nobuichi ; Jinnouchi, Hideaki ; Gosho, Masahiko ; Shimomura, Iichiro ; Watada, Hirotaka</creator><creatorcontrib>Mita, Tomoya ; Katakami, Naoto ; Yoshii, Hidenori ; Onuma, Tomio ; Kaneto, Hideaki ; Osonoi, Takeshi ; Shiraiwa, Toshihiko ; Kosugi, Keisuke ; Umayahara, Yutaka ; Yamamoto, Tsunehiko ; Yokoyama, Hiroki ; Kuribayashi, Nobuichi ; Jinnouchi, Hideaki ; Gosho, Masahiko ; Shimomura, Iichiro ; Watada, Hirotaka ; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial</creatorcontrib><description>Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1-dependent and -independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
This prospective, randomized, open-label, blinded-end point, multicenter, parallel-group, comparative study included 341 patients with T2DM free of a history of apparent cardiovascular diseases recruited at 11 clinical units and randomly allocated to treatment with alogliptin (n = 172) or conventional treatment (n = 169). Primary outcomes were changes in mean common and maximum intima-media thickness (IMT) of the carotid artery measured by carotid arterial echography during a 24-month treatment period.
Alogliptin treatment had a more potent glucose-lowering effect than the conventional treatment (-0.3 ± 0.7% vs. -0.1 ± 0.8%, P = 0.004) without an increase of hypoglycemia. Changes in the mean common and the right and left maximum IMT of the carotid arteries were significantly greater after alogliptin treatment than after conventional treatment (-0.026 mm [SE 0.009] vs. 0.005 mm [SE 0.009], P = 0.022; -0.045 mm [SE 0.018] vs. 0.011 mm [SE 0.017], P = 0.025, and -0.079 mm [SE 0.018] vs. -0.015 mm [SE 0.018], P = 0.013, respectively).
Alogliptin treatment attenuated the progression of carotid IMT in patients with T2DM free of apparent cardiovascular disease compared with the conventional treatment.</description><identifier>ISSN: 0149-5992</identifier><identifier>EISSN: 1935-5548</identifier><identifier>DOI: 10.2337/dc15-0781</identifier><identifier>PMID: 26628419</identifier><identifier>CODEN: DICAD2</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Aged ; Atherosclerosis ; Atherosclerosis - prevention & control ; Blood Glucose ; Cardiovascular disease ; Carotid Arteries - drug effects ; Carotid Arteries - pathology ; Carotid Artery Diseases - drug therapy ; Carotid Intima-Media Thickness ; Comparative analysis ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Disease Progression ; Female ; Glucagon-Like Peptide 1 - metabolism ; Glucose ; Humans ; Hypoglycemic Agents - therapeutic use ; Japan ; Male ; Medical treatment ; Middle Aged ; Peptides ; Piperidines - therapeutic use ; Prospective Studies ; Uracil - analogs & derivatives ; Uracil - therapeutic use</subject><ispartof>Diabetes care, 2016-01, Vol.39 (1), p.139-148</ispartof><rights>2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.</rights><rights>Copyright American Diabetes Association Jan 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a371t-48b88db2b552e56bf8c207dbcef13e91d4f74a4a21d175786a8ac5d48903ef043</citedby><cites>FETCH-LOGICAL-a371t-48b88db2b552e56bf8c207dbcef13e91d4f74a4a21d175786a8ac5d48903ef043</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26628419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mita, Tomoya</creatorcontrib><creatorcontrib>Katakami, Naoto</creatorcontrib><creatorcontrib>Yoshii, Hidenori</creatorcontrib><creatorcontrib>Onuma, Tomio</creatorcontrib><creatorcontrib>Kaneto, Hideaki</creatorcontrib><creatorcontrib>Osonoi, Takeshi</creatorcontrib><creatorcontrib>Shiraiwa, Toshihiko</creatorcontrib><creatorcontrib>Kosugi, Keisuke</creatorcontrib><creatorcontrib>Umayahara, Yutaka</creatorcontrib><creatorcontrib>Yamamoto, Tsunehiko</creatorcontrib><creatorcontrib>Yokoyama, Hiroki</creatorcontrib><creatorcontrib>Kuribayashi, Nobuichi</creatorcontrib><creatorcontrib>Jinnouchi, Hideaki</creatorcontrib><creatorcontrib>Gosho, Masahiko</creatorcontrib><creatorcontrib>Shimomura, Iichiro</creatorcontrib><creatorcontrib>Watada, Hirotaka</creatorcontrib><creatorcontrib>Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial</creatorcontrib><title>Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)</title><title>Diabetes care</title><addtitle>Diabetes Care</addtitle><description>Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1-dependent and -independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
This prospective, randomized, open-label, blinded-end point, multicenter, parallel-group, comparative study included 341 patients with T2DM free of a history of apparent cardiovascular diseases recruited at 11 clinical units and randomly allocated to treatment with alogliptin (n = 172) or conventional treatment (n = 169). Primary outcomes were changes in mean common and maximum intima-media thickness (IMT) of the carotid artery measured by carotid arterial echography during a 24-month treatment period.
Alogliptin treatment had a more potent glucose-lowering effect than the conventional treatment (-0.3 ± 0.7% vs. -0.1 ± 0.8%, P = 0.004) without an increase of hypoglycemia. Changes in the mean common and the right and left maximum IMT of the carotid arteries were significantly greater after alogliptin treatment than after conventional treatment (-0.026 mm [SE 0.009] vs. 0.005 mm [SE 0.009], P = 0.022; -0.045 mm [SE 0.018] vs. 0.011 mm [SE 0.017], P = 0.025, and -0.079 mm [SE 0.018] vs. -0.015 mm [SE 0.018], P = 0.013, respectively).
Alogliptin treatment attenuated the progression of carotid IMT in patients with T2DM free of apparent cardiovascular disease compared with the conventional treatment.</description><subject>Aged</subject><subject>Atherosclerosis</subject><subject>Atherosclerosis - prevention & control</subject><subject>Blood Glucose</subject><subject>Cardiovascular disease</subject><subject>Carotid Arteries - drug effects</subject><subject>Carotid Arteries - pathology</subject><subject>Carotid Artery Diseases - drug therapy</subject><subject>Carotid Intima-Media Thickness</subject><subject>Comparative analysis</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glucagon-Like Peptide 1 - metabolism</subject><subject>Glucose</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Japan</subject><subject>Male</subject><subject>Medical treatment</subject><subject>Middle Aged</subject><subject>Peptides</subject><subject>Piperidines - therapeutic use</subject><subject>Prospective Studies</subject><subject>Uracil - analogs & derivatives</subject><subject>Uracil - therapeutic use</subject><issn>0149-5992</issn><issn>1935-5548</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkdFu0zAUhi0EYmVwwQsgS9xs0gJ2bCcOd1HXjUmTqLQiLiMnPl49pXFmO5P6qLwNzlpAghv72P7-8x_rR-g9JZ9yxsrPuqMiI6WkL9CCVkxkQnD5Ei0I5VUmqio_QW9CeCCEcC7la3SSF0UuOa0W6Gfdu_vejtEOF1jhSztCqvW-x-vnQgXAHN8MW9va6PwFXnt4giEGHLeQDu7eQwjWDdgZvFTeJQ2u05t3oevn1QZsB7xW0T7Lfti4xZv9CDhPbqqFCOEL3qRmd3HS-7nN0cI-AV4ZA11Spdu_g-LkdpDa7j-vs7v1qr7M6vO36JVRfYB3x_0Ufb9abZZfs9tv1zfL-jZTrKQx47KVUrd5K0QOomiN7HJS6rYDQxlUVHNTcsVVTjUtRSkLJVUnNJcVYWAIZ6fo7NB39O5xghCbnQ0d9L0awE2hSSpaFBUrZEI__oM-uMkPabqZKgkrGJup8wPVpR8FD6YZvd0pv28oaea8mznvZs47sR-OHad2B_oP-Ttg9guiFaeY</recordid><startdate>201601</startdate><enddate>201601</enddate><creator>Mita, Tomoya</creator><creator>Katakami, Naoto</creator><creator>Yoshii, Hidenori</creator><creator>Onuma, Tomio</creator><creator>Kaneto, Hideaki</creator><creator>Osonoi, Takeshi</creator><creator>Shiraiwa, Toshihiko</creator><creator>Kosugi, Keisuke</creator><creator>Umayahara, Yutaka</creator><creator>Yamamoto, Tsunehiko</creator><creator>Yokoyama, Hiroki</creator><creator>Kuribayashi, Nobuichi</creator><creator>Jinnouchi, Hideaki</creator><creator>Gosho, Masahiko</creator><creator>Shimomura, Iichiro</creator><creator>Watada, Hirotaka</creator><general>American Diabetes Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>201601</creationdate><title>Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)</title><author>Mita, Tomoya ; Katakami, Naoto ; Yoshii, Hidenori ; Onuma, Tomio ; Kaneto, Hideaki ; Osonoi, Takeshi ; Shiraiwa, Toshihiko ; Kosugi, Keisuke ; Umayahara, Yutaka ; Yamamoto, Tsunehiko ; Yokoyama, Hiroki ; Kuribayashi, Nobuichi ; Jinnouchi, Hideaki ; Gosho, Masahiko ; Shimomura, Iichiro ; Watada, Hirotaka</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a371t-48b88db2b552e56bf8c207dbcef13e91d4f74a4a21d175786a8ac5d48903ef043</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Atherosclerosis</topic><topic>Atherosclerosis - prevention & control</topic><topic>Blood Glucose</topic><topic>Cardiovascular disease</topic><topic>Carotid Arteries - drug effects</topic><topic>Carotid Arteries - pathology</topic><topic>Carotid Artery Diseases - drug therapy</topic><topic>Carotid Intima-Media Thickness</topic><topic>Comparative analysis</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glucagon-Like Peptide 1 - metabolism</topic><topic>Glucose</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Japan</topic><topic>Male</topic><topic>Medical treatment</topic><topic>Middle Aged</topic><topic>Peptides</topic><topic>Piperidines - therapeutic use</topic><topic>Prospective Studies</topic><topic>Uracil - analogs & derivatives</topic><topic>Uracil - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mita, Tomoya</creatorcontrib><creatorcontrib>Katakami, Naoto</creatorcontrib><creatorcontrib>Yoshii, Hidenori</creatorcontrib><creatorcontrib>Onuma, Tomio</creatorcontrib><creatorcontrib>Kaneto, Hideaki</creatorcontrib><creatorcontrib>Osonoi, Takeshi</creatorcontrib><creatorcontrib>Shiraiwa, Toshihiko</creatorcontrib><creatorcontrib>Kosugi, Keisuke</creatorcontrib><creatorcontrib>Umayahara, Yutaka</creatorcontrib><creatorcontrib>Yamamoto, Tsunehiko</creatorcontrib><creatorcontrib>Yokoyama, Hiroki</creatorcontrib><creatorcontrib>Kuribayashi, Nobuichi</creatorcontrib><creatorcontrib>Jinnouchi, Hideaki</creatorcontrib><creatorcontrib>Gosho, Masahiko</creatorcontrib><creatorcontrib>Shimomura, Iichiro</creatorcontrib><creatorcontrib>Watada, Hirotaka</creatorcontrib><creatorcontrib>Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Diabetes care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mita, Tomoya</au><au>Katakami, Naoto</au><au>Yoshii, Hidenori</au><au>Onuma, Tomio</au><au>Kaneto, Hideaki</au><au>Osonoi, Takeshi</au><au>Shiraiwa, Toshihiko</au><au>Kosugi, Keisuke</au><au>Umayahara, Yutaka</au><au>Yamamoto, Tsunehiko</au><au>Yokoyama, Hiroki</au><au>Kuribayashi, Nobuichi</au><au>Jinnouchi, Hideaki</au><au>Gosho, Masahiko</au><au>Shimomura, Iichiro</au><au>Watada, Hirotaka</au><aucorp>Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) Trial</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A)</atitle><jtitle>Diabetes care</jtitle><addtitle>Diabetes Care</addtitle><date>2016-01</date><risdate>2016</risdate><volume>39</volume><issue>1</issue><spage>139</spage><epage>148</epage><pages>139-148</pages><issn>0149-5992</issn><eissn>1935-5548</eissn><coden>DICAD2</coden><abstract>Recent experimental studies have shown that dipeptidyl peptidase 4 (DPP-4) inhibitors have antiatherosclerotic benefits in glucagon-like peptide 1-dependent and -independent manners. The current study investigated the effects of alogliptin, a DPP-4 inhibitor, on the progression of carotid atherosclerosis in patients with type 2 diabetes mellitus (T2DM).
This prospective, randomized, open-label, blinded-end point, multicenter, parallel-group, comparative study included 341 patients with T2DM free of a history of apparent cardiovascular diseases recruited at 11 clinical units and randomly allocated to treatment with alogliptin (n = 172) or conventional treatment (n = 169). Primary outcomes were changes in mean common and maximum intima-media thickness (IMT) of the carotid artery measured by carotid arterial echography during a 24-month treatment period.
Alogliptin treatment had a more potent glucose-lowering effect than the conventional treatment (-0.3 ± 0.7% vs. -0.1 ± 0.8%, P = 0.004) without an increase of hypoglycemia. Changes in the mean common and the right and left maximum IMT of the carotid arteries were significantly greater after alogliptin treatment than after conventional treatment (-0.026 mm [SE 0.009] vs. 0.005 mm [SE 0.009], P = 0.022; -0.045 mm [SE 0.018] vs. 0.011 mm [SE 0.017], P = 0.025, and -0.079 mm [SE 0.018] vs. -0.015 mm [SE 0.018], P = 0.013, respectively).
Alogliptin treatment attenuated the progression of carotid IMT in patients with T2DM free of apparent cardiovascular disease compared with the conventional treatment.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>26628419</pmid><doi>10.2337/dc15-0781</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-5992 |
| ispartof | Diabetes care, 2016-01, Vol.39 (1), p.139-148 |
| issn | 0149-5992 1935-5548 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1751669368 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Atherosclerosis Atherosclerosis - prevention & control Blood Glucose Cardiovascular disease Carotid Arteries - drug effects Carotid Arteries - pathology Carotid Artery Diseases - drug therapy Carotid Intima-Media Thickness Comparative analysis Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Disease Progression Female Glucagon-Like Peptide 1 - metabolism Glucose Humans Hypoglycemic Agents - therapeutic use Japan Male Medical treatment Middle Aged Peptides Piperidines - therapeutic use Prospective Studies Uracil - analogs & derivatives Uracil - therapeutic use |
| title | Alogliptin, a Dipeptidyl Peptidase 4 Inhibitor, Prevents the Progression of Carotid Atherosclerosis in Patients With Type 2 Diabetes: The Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T11%3A51%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Alogliptin,%20a%20Dipeptidyl%20Peptidase%204%20Inhibitor,%20Prevents%20the%20Progression%20of%20Carotid%20Atherosclerosis%20in%20Patients%20With%20Type%202%20Diabetes:%20The%20Study%20of%20Preventive%20Effects%20of%20Alogliptin%20on%20Diabetic%20Atherosclerosis%20(SPEAD-A)&rft.jtitle=Diabetes%20care&rft.au=Mita,%20Tomoya&rft.aucorp=Collaborators%20on%20the%20Study%20of%20Preventive%20Effects%20of%20Alogliptin%20on%20Diabetic%20Atherosclerosis%20(SPEAD-A)%20Trial&rft.date=2016-01&rft.volume=39&rft.issue=1&rft.spage=139&rft.epage=148&rft.pages=139-148&rft.issn=0149-5992&rft.eissn=1935-5548&rft.coden=DICAD2&rft_id=info:doi/10.2337/dc15-0781&rft_dat=%3Cproquest_cross%3E1751669368%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1757036338&rft_id=info:pmid/26628419&rfr_iscdi=true |